Jazz Securities Designated Activity Company Credit Rating

Resultados 1 - 41 de 41

Página 1 de 1 Next

Filtrar por:

Fecha	Tipo de Informe	Title	Source
25 Jan 2024	Rating Action	Moody's upgrades Jazz Pharma's CFR to Ba2; stable outlook	Moody's Investors Service
27 Jul 2023	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
20 Jan 2023	Rating Action	Moody's revises Jazz Pharma outlook to positive; affirms Ba3 CFR	Moody's Investors Service
04 Oct 2022	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
11 Apr 2022	Rating Action	Moody's affirms Jazz Pharma at Ba3; revises outlook to stable from negative	Moody's Investors Service
08 Nov 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Jazz Pharmaceuticals plc	Moody's Investors Service
13 May 2021	Covenant Quality Assessment	Jazz Securities Designated Activity Company: Covenant Quality Post-Sale Snapshot: $1,500m 4.375% Senior Secured Notes due 2029	Moody's Investors Service
20 Apr 2021	Rating Action	Moody's assigns Ba2 to Jazz Pharma's secured notes; negative outlook	Moody's Investors Service
09 Apr 2021	Rating Action	Moody's assigns Ba2 to Jazz Pharma's new secured credit facilities; negative outlook	Moody's Investors Service
05 Feb 2021	Credit Opinion	Jazz Securities Designated Activity Company: Update following change to ratings under review for downgrade	Moody's Investors Service
04 Feb 2021	Rating Action	Moody's reviews Jazz Pharma's ratings for downgrade	Moody's Investors Service
15 Dec 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Jazz Securities Designated Activity Company	Moody's Investors Service
05 Aug 2020	LGD Assessment	Jazz Pharma LGD	Moody's Investors Service
24 Jul 2020	Credit Opinion	Jazz Securities Designated Activity Company: Update to credit analysis - Xywav and Zepzelca launches will help mitigate approaching Xyrem generics in 2023	Moody's Investors Service
09 Jun 2020	Announcement	Moody's: Jazz's new exchangeable notes issuance is credit negative	Moody's Investors Service
09 Jun 2020	Issuer Comment	Jazz Securities Designated Activity Company: New exchangeable notes issuance is credit negative	Moody's Investors Service
14 Jan 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Jazz Securities Designated Activity Company	Moody's Investors Service
02 Aug 2019	LGD Assessment	Jazz Securities Designated Activity Company	Moody's Investors Service
24 Jul 2019	Credit Opinion	Jazz Securities Designated Activity Company: Update to credit analysis - ongoing Sunosi launch will help mitigate 2023 Xyrem generic competition	Moody's Investors Service
15 Feb 2019	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Jazz Securities Designated Activity Company	Moody's Investors Service
30 Jul 2018	Credit Opinion	Jazz Securities Designated Activity Company: Update to credit analysis - Xyrem generic competition in 2023 will prompt acquisitions	Moody's Investors Service
10 Jul 2018	LGD Assessment	Jazz Pharmaceuticals plc	Moody's Investors Service
22 May 2018	Rating Action	Moody's assigns Ba1 to Jazz Pharma's senior secured credit facilities	Moody's Investors Service
27 Sep 2017	LGD Assessment	Jazz Securities Limited	Moody's Investors Service
18 Aug 2017	Credit Opinion	Jazz Securities Limited: Update following refinancing of revolving credit facility with convertible notes and upgrade of secured debt rating	Moody's Investors Service
18 Aug 2017	Rating Action	Moody's raises Jazz's sr. secured to Ba1 from Ba2; affirms Ba3 CFR	Moody's Investors Service
12 Apr 2017	Credit Opinion	Jazz Securities Limited: Update following outlook change to stable from negative	Moody's Investors Service
11 Apr 2017	Rating Action	Moody's affirms Jazz Pharma at Ba3; revises outlook to stable from negative	Moody's Investors Service
28 Dec 2016	LGD Assessment	Jazz Securities Limited	Moody's Investors Service
29 Jul 2016	Announcement	Moody's: Xyrem Patent Loss Is Credit Negative, but Other Patents Still Exist; Ratings Unaffected	Moody's Investors Service
29 Jul 2016	Issuer Comment	Jazz Securities Limited: Xyrem Patent Decision Is Credit Negative for Jazz, but Other Patents Still Valid; Ratings Unaffected	Moody's Investors Service
13 Jul 2016	Announcement	Moody's: Jazz's Upsized revolving credit facility is positive for liquidity; ratings unaffected	Moody's Investors Service
13 Jul 2016	Issuer Comment	Jazz Securities Limited: Jazz's Upsized Revolving Credit Facility is positive for liquidity; ratings unaffected	Moody's Investors Service
06 Jul 2016	LGD Assessment	Jazz LGD 2016-June	Moody's Investors Service
06 Jun 2016	Credit Opinion	Jazz Securities Limited: Update following announced acquisition of Celator Pharmaceuticals, Inc.	Moody's Investors Service
06 Jun 2016	Issuer Comment	Jazz Pharmaceuticals' Planned Acquisition of Celator Is Credit Negative	Moody's Investors Service
01 Jun 2016	Rating Action	Moody's affirms Jazz's Ba3 CFR; Outlook to Negative	Moody's Investors Service
01 Apr 2016	Announcement	Moody's: Approval of Jazz's Defitelio by the FDA is credit positive; ratings unaffected	Moody's Investors Service
31 Mar 2016	Issuer Comment	Jazz Securities Limited: FDA Approval of Jazz's Defitelio is credit positive; ratings unaffected	Moody's Investors Service
20 Jun 2015	Credit Opinion	Jazz Securities Limited	Moody's Investors Service
19 Jun 2015	Rating Action	Moody's assigns Ba2 to Jazz's new senior secured bank facilities; stable outlook	Moody's Investors Service

Resultados 1 - 41 de 41

Página 1 de 1 Next

Informes & Calificaciones

Productos & Soluciones

Noticias & Eventos

Usuarios Registrados

¿No se ha registrado?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: